|
01 May 2019 |
Abeona Therapeutics Reports Preclinical Data Demonstrating Broad Therapeutic Potential of AIM™ Gene Therapy in Retinal Diseases at Association for Research in Vision and Ophthalmology Annual Meeting
|
|
01 May 2019 |
Cell Medica Collaborators, Baylor College of Medicine and Texas Children’s Hospital, Present Preclinical Data for an off-the-shelf CAR-NKT Therapy Platform at American Society of Gene & Cell Therapy 22nd Annual Meeting
|
|
01 May 2019 |
Sigilon Therapeutics Delivers Oral Presentation on SIG-001 for Hemophilia A at 2019 ASGCT Meeting
|
|
01 May 2019 |
Triumvira Submits Investigational New Drug (IND) Application to the FDA and Clinical Trial Application (CTA) to Health Canada to Evaluate TAC01-CD19, a T Cell Antigen Coupler Therapy, in Ph 1/2 TACTIC-19 Trial
|
|
30 Apr 2019 |
Tessa Therapeutics, in Collaboration with Baylor College of Medicine, Presents Preclinical Results Showing Enhanced T Cell Responses Against HER2-Positive Solid Tumors Using Novel Combination CAR T Cell Therapy
|
|
30 Apr 2019 |
Dynacure Announces Approval of Clinical Trial Application for DYN101, an Antisense Medicine to Treat Rare Disease 'Centronuclear Myopathies'
|
|
30 Apr 2019 |
Cell Medica Collaborators, Baylor College of Medicine and Texas Children’s Hospital, Present Positive Early Patient Data From CAR-NKT Neuroblastoma Trial at American Society Of Gene & Cell Therapy 22nd Annual Meeting
|
|
29 Apr 2019 |
AVROBIO, Inc. Announces FDA Clearance of Investigational New Drug Application for AVR-RD-01 Gene Therapy for the Treatment of Fabry Disease
|
|
26 Apr 2019 |
Orchard Therapeutics Announces First Patient Dosed with Cryopreserved Formulation of OTL-103 Gene Therapy for the Treatment of Wiskott-Aldrich Syndrome
|
|
24 Apr 2019 |
Arrowhead Begins Triple Combination Cohort in Chronic HBV Patients and Earns $25 Million Milestone Payment from Janssen
|
|
24 Apr 2019 |
TC BioPharm Initiates Phase I Trial of Allogeneic Gamma Delta T Cell Therapy in Acute Myeloid Leukemia Patients
|
|
24 Apr 2019 |
Rexgenero Presents Update on Phase III Clinical Trials with REX-001, a Cell-based Therapy for Critical Limb Ischaemia
|
|
23 Apr 2019 |
HEALIOS K.K. Announces Enrollment of First Patient in Japan in the ONE-BRIDGE Study of MultiStem® Treatment for Acute Respiratory Distress Syndrome
|
|
23 Apr 2019 |
Gracell Bio Announces FasT CAR-T, a Breakthrough Technology for Hematological Malignancies
|
|
23 Apr 2019 |
OncoSec Announces Triple Combination Immunotherapy Clinical Trial Of TAVO™, Epacadostat And KEYTRUDA® In Squamous Cell Head And Neck (SCCHN) Cancer
|
|
19 Apr 2019 |
St. Jude Children’s Research Hospital publishes results of Lentiviral Gene Therapy for Treatment of Infants with X-linked Severe Combined Immunodeficiency in New England Journal of Medicine
|
|
19 Apr 2019 |
Inovio Publishes Cancer Killing Data of Its Transformative DNA-encoded Bi-specific T Cell Engagers (dBiTEs™) in a Peer-reviewed Journal
|
|
18 Apr 2019 |
Talaris Therapeutics, Inc. Announces Promising Phase 2 Data of Novel, Allogeneic Cell Therapy in Living Donor Kidney Transplant Recipients
|
|
18 Apr 2019 |
Talaris Therapeutics, Inc. Announces $100M Series A Financing to Advance Its Novel, Allogeneic Cell Therapy Through Late-Stage Clinical Development
|
|
17 Apr 2019 |
Wave Life Sciences Announces Suvodirsen Phase 1 Safety and Tolerability Data and Phase 2/3 Clinical Trial Design
|
|
17 Apr 2019 |
Precision BioSciences Announces Dosing of First Patient in Off-The-Shelf CAR T Cell Therapy Phase 1/2a Clinical Trial
|
|
17 Apr 2019 |
Biomica Initiates Pre-clinical Studies in Its Immuno-oncology Program
|
|
17 Apr 2019 |
AANS 2019: SB623 Demonstrated Statistically Significant Improvement in Motor Function Among Patients with Chronic Motor Deficit from Traumatic Brain Injury (TBI)
|
|
17 Apr 2019 |
GenSight Biologics Reports Positive Follow-up Results at Week 72 of the RESCUE Phase III Clinical Trial of GS010 in Leber Hereditary Optic Neuropathy (LHON)
|
|
16 Apr 2019 |
Tessa Therapeutics Announces Collaboration with Merck Investigating the Combination of KEYTRUDA® (pembrolizumab) and Virus-Specific T Cell Therapy Targeting Human Papillomavirus in Cervical Cancer
|
